Telik Announces Expansion of Phase 2 Trial of Telcyta in Hematologic Malignancies

Telik, Inc. TELK today announced that the Phase 2 investigator-led Telcyta trial in hematologic malignancies has been expanded to an additional investigational site, Memorial Sloan-Kettering Cancer Center. Based upon the results observed in Stage 1 of the trial, which is being conducted at the Robert Wood Johnson University Hospital under the direction of Joseph R. Bertino, MD of The Cancer Institute of New Jersey, an additional 10 patients with chemotherapy resistant multiple myeloma may be enrolled. Additional trial investigators at MSKCC are Sergio A. Giralt, MD and Nikoletta Lendvai, MD, PhD.